Skip to main content

Biocryst Pharmaceuticals

BioCryst Pharmaceuticals Inc is a commercial-stage biopharmaceutical enterprise headquartered in Durham, North Carolina. The company designs, develops, and commercializes novel small-molecule oral therapeutics targeted at rare and serious diseases driven by immune system dysfunction. Its primary commercial product is Orladeyo, an oral preventative treatment for hereditary angioedema. Principal revenue is derived through direct commercial sales of its approved pharmaceutical products alongside research collaboration grants. The enterprise serves clinical physicians and patients globally. BioCryst Pharmaceuticals Inc is publicly traded on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Biocryst Pharmaceuticals.

Legal name
BIOCRYST PHARMACEUTICALS
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding Biocryst Pharmaceuticals

Loading...